Denali Therapeutics Inc. (DNLI) PT Lowered to $36 at Goldman Sachs, Following Earnings
Tweet
Share
E-mailGet Alerts DNLI Hot Sheet
Price: $24.40 -1.69%
Rating Summary:
22 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
22 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Goldman Sachs analyst Salveen Richter lowered the price target on Denali Therapeutics Inc. (NASDAQ: DNLI) to $36.00 (from $37.00) while maintaining a Buy rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
- Va Tech Wabag Ltd. (VATW:IN) PT Raised to INR2,410 at ICICI Securities
- Sansera Engineering Ltd (SANSERA:IN) PT Raised to INR4,250 at ICICI Securities
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Goldman Sachs, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
